
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Oramed Pharmaceuticals Inc (ORMP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: ORMP (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -66.91% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.58M USD | Price to earnings Ratio 4.55 | 1Y Target Price 3.25 |
Price to earnings Ratio 4.55 | 1Y Target Price 3.25 | ||
Volume (30-day avg) 385032 | Beta 1.77 | 52 Weeks Range 2.00 - 3.67 | Updated Date 02/16/2025 |
52 Weeks Range 2.00 - 3.67 | Updated Date 02/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -4.12% | Return on Equity (TTM) 2.89% |
Valuation
Trailing PE 4.55 | Forward PE - | Enterprise Value -52378207 | Price to Sales(TTM) 141.54 |
Enterprise Value -52378207 | Price to Sales(TTM) 141.54 | ||
Enterprise Value to Revenue 2.86 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 40769000 | Shares Floating 33658562 |
Shares Outstanding 40769000 | Shares Floating 33658562 | ||
Percent Insiders 10.62 | Percent Institutions 17.32 |
AI Summary
Oramed Pharmaceuticals Inc.: A Comprehensive Overview
Company Profile:
History and Background: Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a clinical-stage biopharmaceutical company founded in 1999 with headquarters in Jerusalem, Israel. The company focuses on developing and commercializing oral drug delivery systems for various diseases, including diabetes and other metabolic disorders.
Core Business Areas:
- Oral Insulin: Oramed's flagship product is ORMD-0801, an oral formulation of insulin currently in Phase III clinical trials for the treatment of type 2 diabetes.
- GLP-1 Receptor Agonists: The company is also developing oral formulations of GLP-1 receptor agonists, which are hormones that stimulate insulin secretion and regulate blood sugar levels.
- Other Programs: Oramed has a pipeline of other oral drug delivery candidates targeting conditions like obesity, inflammatory bowel disease, and central nervous system disorders.
Leadership and Corporate Structure:
- Nadav Kidron, CEO and Chairman of the Board
- Dr. Michael Davidson, Chief Medical Officer
- Dr. Peter Koshy, Chief Business Officer
- The company has a Board of Directors consisting of experienced professionals in the pharmaceutical industry.
Top Products and Market Share:
- ORMD-0801: This oral insulin formulation is not yet approved for commercialization. However, it has shown promising results in clinical trials, demonstrating the potential to significantly impact the type 2 diabetes market.
- ORMD-0901: Oramed's oral GLP-1 receptor agonist is in Phase Ib clinical trials and holds promise as a potential non-injectable alternative for diabetes treatment.
Market Share Analysis:
- The global insulin market is estimated to reach $60 billion by 2025. Oramed's oral insulin could potentially capture a significant share of this market, offering a more convenient and accessible treatment option for diabetic patients.
- The GLP-1 receptor agonist market is expected to reach $20 billion by 2027. Oramed's oral GLP-1 could compete with existing injectable therapies and offer a more patient-friendly option.
Total Addressable Market:
- Type 2 Diabetes: The global type 2 diabetes population is estimated at over 463 million people, representing a significant opportunity for Oramed's oral therapies.
- Other Metabolic Disorders: The company's pipeline targets other large markets, including obesity and inflammatory bowel disease, further expanding its total addressable market.
Financial Performance:
- As a clinical-stage company, Oramed's revenue is currently limited to research and development grants.
- The company has reported net losses in recent years due to ongoing research and development expenses.
- Oramed's cash runway is sufficient to support its operations into 2024.
Dividends and Shareholder Returns:
- Oramed does not currently pay dividends due to its status as a pre-revenue company.
- Shareholder returns have been negative in recent years, reflecting the company's focus on research and development.
Growth Trajectory:
- The successful development and commercialization of ORMD-0801 and ORMD-0901 could drive significant future growth for Oramed.
- The company's focus on oral drug delivery technology positions it well for potential long-term growth in the pharmaceutical market.
- Partnerships and collaborations with other pharmaceutical companies could also contribute to future growth.
Market Dynamics:
- The pharmaceutical industry is characterized by rapid innovation, intense competition, and increasing regulatory scrutiny.
- Oramed's success will depend on its ability to navigate these challenges and bring its novel oral drug delivery systems to market effectively.
Competitors:
- Novo Nordisk (NVO): Leading insulin manufacturer with a large market share.
- Eli Lilly (LLY): Another major insulin producer with a strong presence in diabetes treatment.
- Sanofi (SNY): A pharmaceutical giant with a diverse portfolio of diabetes medications.
- AstraZeneca (AZN): Developer of GLP-1 receptor agonists for diabetes treatment.
Market Share Comparison:
- Oramed does not currently have any marketed products and therefore holds no market share in the diabetes or GLP-1 agonist markets.
- The company's success will depend on gaining market share from established players like those mentioned above.
Competitive Advantages and Disadvantages:
Advantages:
- Novel oral drug delivery technology
- Potential for improved patient adherence and convenience
- Large addressable markets
Disadvantages:
- Lack of approved products
- Intense competition from established players
- High research and development costs
Potential Challenges and Opportunities:
Challenges:
- Demonstrating the safety and efficacy of oral insulin and other pipeline products
- Gaining regulatory approval for commercialization
- Competing with established pharmaceutical companies
Opportunities:
- Expanding into new markets with oral drug delivery systems
- Partnering with other pharmaceutical companies for market access
- Leveraging technological advancements to develop innovative treatments
Recent Acquisitions:
Oramed has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
- Based on an AI-model analysis considering financial health, market position, and future prospects, Oramed Pharmaceuticals receives a rating of 5 out of 10.
- This rating reflects the company's potential for growth due to its novel technology and large addressable markets. However, it also acknowledges the challenges Oramed faces in bringing its products to market and competing with established players.
Sources and Disclaimers:
- Data for this analysis was gathered from Oramed Pharmaceuticals Inc.'s website, SEC filings, and various industry reports.
- This information is provided for educational purposes only and should not be considered investment advice.
About Oramed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-04-21 | President, CEO & Executive Chairman Mr. Nadav Kidron Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.oramed.com |
Full time employees - | Website https://www.oramed.com |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.